TITLE:
Development of a Method for Identification and Quantification of Sulfadiazine and Pyrimethamine in Serum of Congenital Toxoplasmosis Pediatric Patients
AUTHORS:
Maria Elena Marson, Fleitas Ulises, Pérez Montilla Carlos, Prospitti Anabela, Altcheh Jaime, Moroni Samanta, Moscatelli Guillermo, García Bournissen Facundo, Mastrantonio Guido
KEYWORDS:
Toxoplasmosis, Bioanalytics, Pediatric Pharmacology, Therapeutic Drug Monitoring, Neglected Diseases
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.12 No.8,
August
27,
2021
ABSTRACT: Infection with Toxoplasma
gondii, is one of the most widespread zoonoses in the world. Congenital Toxoplasmosis
(CT) is particularly risky due to its fetal complications.
Sulfadiazine (SDZ) and Pyrimethamine (PYR) are usually used for CT treatment in Argentina, to prevent
morbidity. Due to the lack of commercial pediatric formulations, these
must be prepared in the hospital pharmacy. This is the first report of serum
concentrations measures in pediatric CT therapy for this combination of drugs. A
bioanalytical method was developed for identification and simultaneous
quantification of SDZ and PYR by High Performance Liquid Chromatography (HPLC)
with UV detection. The validated method was applied to residual serum samples
obtained from 6 pediatric patients undergoing treatment with SDZ 42.20 a 93.70
mg/kg/day and PYR 0.77 a 2.70 mg/kg/day.
Sample pretreatment consisted on a deproteinization
step followed by centrifugation and then injection of supernatant. Limit
of Detection (LOD) and Quantification (LOQ) were (0.17 ± 0.02 and 0.13 ± 0.02)
μg/mL and (0.46 ± 0.01 and 0.36 ± 0.01) μg/mL for SDZ and PYR respectively,
with an appropriate linear range. Concentrations range found were ( - 162.04 ± 0.02) μg/mL for SDZ and ( - 7.30 ± 0.03) μg/mL for PYR. We developed and validated in real pediatric samples, an
acute, precise and low-cost method for
quantification of SDZ and PYR using a non-sophisticate chromatographic equipment, suitable for hospital therapeutic monitoring
for public health system.